Literature DB >> 20690058

Immunohistochemical analysis of tissue microarrays.

Ronald Simon1, Martina Mirlacher, Guido Sauter.   

Abstract

Immunohistochemistry (IHC) is the gold standard methodology for in-situ protein expression analysis in tissue samples. The combination of IHC and tissue microarray (TMA) technology allows for the simultaneous analysis of hundreds of tissue samples with an unprecedented degree of experimental standardization. The same immunostaining protocols used for conventional large sections can be used for TMAs, including antigen retrieval procedures for staining of routinely archived formalin-fixed tissue samples. The development of optimal IHC protocols is highly important for TMA studies because minor protocol variations often have a marked impact on the outcome of the staining. Preabsorption and isotype-specific control experiments should be included as the last step in protocol development to proof target protein-specific binding. Such controls are particularly important for new antibodies with unknown staining patterns.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690058     DOI: 10.1007/978-1-60761-806-5_12

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  24 in total

1.  Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Authors:  David L Rimm; Torsten O Nielsen; Scott D Jewell; Daniel C Rohrer; Gloria Broadwater; Frederic Waldman; Kisha A Mitchell; Baljit Singh; Gregory J Tsongalis; Wendy L Frankel; Anthony M Magliocco; Jonathan F Lara; Eric D Hsi; Ira J Bleiweiss; Sunil S Badve; Beiyun Chen; Peter M Ravdin; Richard L Schilsky; Ann Thor; Donald A Berry
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  Silencing of CXCR2 and CXCR7 protects against esophageal cancer.

Authors:  Kai Wu; Lingling Cui; Yang Yang; Jia Zhao; Dengyan Zhu; Donglei Liu; Chunyang Zhang; Yu Qi; Xiangnan Li; Weihao Li; Song Zhao
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma.

Authors:  Thomas Knösel; Yuan Chen; Stefanie Hotovy; Utz Settmacher; Annelore Altendorf-Hofmann; Iver Petersen
Journal:  Int J Colorectal Dis       Date:  2012-03-23       Impact factor: 2.571

4.  A benchmark for comparing precision medicine methods in thyroid cancer diagnosis using tissue microarrays.

Authors:  Ching-Wei Wang; Yu-Ching Lee; Evelyne Calista; Fan Zhou; Hongtu Zhu; Ryohei Suzuki; Daisuke Komura; Shumpei Ishikawa; Shih-Ping Cheng
Journal:  Bioinformatics       Date:  2018-05-15       Impact factor: 6.937

5.  Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo.

Authors:  Jia-Wei Zhang; Fan Zhao; Qing Sun
Journal:  Oncol Lett       Date:  2017-11-20       Impact factor: 2.967

6.  Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.

Authors:  Ying Zhang; Wei Hua; Li-Chun Niu; Shi-Mei Li; Ying-Mei Wang; Lei Shang; Cun Zhang; Wei-Na Li; Rui Wang; Bi-Liang Chen; Xiao-Yan Xin; Ying-Qi Zhang; Jian Wang
Journal:  Tumour Biol       Date:  2016-01-18

7.  The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma.

Authors:  Till Sebastian Clauditz; Thorsten Rieckmann; Mara Borgmann; Agnes Oetting; Felix Meyer; Nikolaus Möckelmann; Conrad Droste; Clara Marie von Bargen; Christina Möller-Koop; Melanie Witt; Kerstin Borgmann; Kai Rothkamm; Christian Betz; Adrian Münscher
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-08       Impact factor: 4.322

8.  FABP1 expression in human tumors: a tissue microarray study on 17,071 tumors.

Authors:  David Dum; Ana Ocokoljic; Maximilian Lennartz; Claudia Hube-Magg; Viktor Reiswich; Doris Höflmayer; Frank Jacobsen; Christian Bernreuther; Patrick Lebok; Guido Sauter; Andreas M Luebke; Eike Burandt; Andreas H Marx; Ronald Simon; Till S Clauditz; Sarah Minner; Anne Menz; Franziska Büscheck; Natalia Gorbokon; Stefan Steurer; Niclas C Blessin; Till Krech
Journal:  Virchows Arch       Date:  2022-08-11       Impact factor: 4.535

9.  p16 upregulation is linked to poor prognosis in ERG negative prostate cancer.

Authors:  Christoph Burdelski; Tatsiana Dieckmann; Asmus Heumann; Claudia Hube-Magg; Martina Kluth; Burkhard Beyer; Thomas Steuber; Raisa Pompe; Markus Graefen; Ronald Simon; Sarah Minner; Maria Christina Tsourlakis; Christina Koop; Jakob Izbicki; Guido Sauter; Till Krech; Thorsten Schlomm; Waldemar Wilczak; Patrick Lebok
Journal:  Tumour Biol       Date:  2016-07-21

10.  ALCAM (CD166) expression and serum levels in pancreatic cancer.

Authors:  Michael Tachezy; Hilke Zander; Andreas H Marx; Phillip R Stahl; Florian Gebauer; Jakob R Izbicki; Maximilian Bockhorn
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.